Seeking To Broaden Market For Feraheme, AMAG Runs Afoul Of DDMAC
This article was originally published in The Pink Sheet Daily
Executive Summary
The prospect of anemic Medicare compensation for Feraheme (ferumoxytol) may have pushed the company to promote the drug in ways that FDA's advertising reviewers think is illegitimate.